All In Biotech

Drug Trial Radar · NCT01642888

A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI

A Phase III Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI (PPD)

Last checked: Nov 19, 2026Latest source record: Apr 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,190

Actual

Start

Sep 2012

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Statens Serum InstitutAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 17, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 28 days, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Tuberculosis (TB) continues to be one of the most serious bacterial infections worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB. The new skin test is named C-Tb. Like the current tuberculin skin test, PPD, the C-Tb test is injected just under the skin and will, when positive, show redness and/or swelling at the injection site while a negative test will leave no reactions. The investigators hope that this new C-Tb skin test will be more precise (specific) than the PPD test, as the PPD test e.g. may show a reaction if the person tested is BCG vaccinated. The aim of this trial is to test the C-Tb skin test in volunteers suspected of having TB disease. With focus on age, HIV status and CD4 count the following analyses are done (in an overall perspective): * To compare the C-Tb test to a blood test, the QuantiFERON test. * To compare the C-Tb test to the PPD test that is currently being used. * To assess the safety of the C-Tb test.

Conditions

  • Tuberculosis

Interventions

  • C-TbBiological

    The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

  • 2 T.U. Tuberculin PPD RT 23 SSIBiological

    The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the diagnostic performance of C-Tb in relation to age, HIV and CD4 countsTime frame: Onset between the injections and 28 days after the injections
  2. To evaluate the clinical safety of C-Tb, with emphasis on children and HIV positive participantsTime frame: Onset between the injections and 28 days after the injections

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Primecure Medicentre, Mercantile Hospital

    Port Elizabeth, Eastern Cape, South Africa

  • Worthwhile Clinical Trials, Lakeview Hospital

    Benoni, Gauteng, South Africa

  • Synnyside Medi-Clinic

    Pretoria, Gauteng, South Africa

  • Synexus Stanza Bopape Clinic

    Pretoria, Gauteng, South Africa

  • Setshaba Research Centre

    Pretoria, Gauteng, South Africa

  • M2 Karl Bremer Hospital

    Bellville, Cape Town, Western Cape, South Africa

  • Tiervlei Trial Centre, Karl Bremer Hospital

    Bellville, Cape Town, Western Cape, South Africa

  • UCT Lung Institute, Groote Schuur Hospital

    Cape Town, Western Cape, South Africa

  • Be Part Yoluntu Centre

    Paarl, Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.